Yongzuo Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Yongzuo Li has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Chujie Li
The M-Lab, Department of Precision Medicine, GROW - Research Institute for Oncology and Reproduction, Maastricht University, Maastricht, the Netherlands
1 shared publication - Tianqing Jiang
School of Pharmacy, Chengdu University, 2025 Chengluo Avenue, Chengdu 610106, China
1 shared publication - Yue Wang
Cell Biology-Inspired Tissue Engineering, Institute for Technology-Inspired, Regenerative Medicine, Maastricht University, 6200 MD Maastricht, The Netherlands
1 shared publication - Zhengwen Li
School of Pharmacy, Chengdu University, 2025 Chengluo Avenue, Chengdu 610106, China
1 shared publication - Zhengyou He
School of Food and Biological Engineering, Chengdu University, Chengdu 610106, China
1 shared publication
Latest Publications
- Open Access
Quercetin and Its Metabolites: Mechanistic Insights as the Basis of Their Therapeutic Potential in NAFLD and HCC
Quercetin, a dietary flavonoid, has demonstrated antioxidant, anti-inflammatory, and anti-tumor activities. Increasing evidence highlights that its metabolites contribute to these health benefits. This review summarizes current knowledge on the molecular mechanisms and therapeutic potential of quercetin and its metabolites in non-alcoholic fatty liver disease (NAFLD) and hepatocellular carcinoma (HCC), with a focus on redox modulation and microbiota interactions. Substantial preclinical evidence supports the protective effects of quercetin and its metabolites in NAFLD and HCC. However, clinical translation is hampered by poor bioavailability, potential redox–drug interactions, and incomplete understanding of the precise molecular mechanisms involved. Future research should prioritize further elucidating the molecular mechanisms, as they represent the foundation for the rational use of quercetin and metabolite-based derivatives in the prevention and treatment of liver-related diseases. In particular, strategies that direct the activity of these bioactive compounds to their desired sites of action—by exploiting differences between normal and cancer cells—warrant more in-depth investigation.
Open AccessQuercetin and Its Metabolites: Mechanistic Insights as the Basis of Their Therapeutic Potential in NAFLD and HCC
Quercetin, a dietary flavonoid, has demonstrated antioxidant, anti-inflammatory, and anti-tumor activities. Increasing evidence highlights that its metabolites contribute to these health benefits. This review summarizes current knowledge on the molecular mechanisms and therapeutic potential of quercetin and its metabolites in non-alcoholic fatty liver disease (NAFLD) and hepatocellular carcinoma (HCC), with a focus on redox modulation and microbiota interactions. Substantial preclinical evidence supports the protective effects of quercetin and its metabolites in NAFLD and HCC. However, clinical translation is hampered by poor bioavailability, potential redox–drug interactions, and incomplete understanding of the precise molecular mechanisms involved. Future research should prioritize further elucidating the molecular mechanisms, as they represent the foundation for the rational use of quercetin and metabolite-based derivatives in the prevention and treatment of liver-related diseases. In particular, strategies that direct the activity of these bioactive compounds to their desired sites of action—by exploiting differences between normal and cancer cells—warrant more in-depth investigation.